Great Lakes Advisors LLC Has $3.94 Million Stock Position in DexCom, Inc. $DXCM

Key Points

• Great Lakes Advisors LLC increased its stake in DexCom, Inc. by 31.0%, acquiring an additional 13,664 shares, bringing its total holdings to approximately $3.94 million.
• Several analysts have recently weighed in on DexCom, with Oppenheimer downgrading the stock from "outperform" to "market perform," while Canaccord Genuity maintained a "buy" rating with a price target of $106.00.
• In insider activity, EVP Michael Jon Brown and Director Mark G. Foletta sold shares of DexCom, with Brown decreasing his ownership by 0.53% and Foletta by 5.10%.

Great Lakes Advisors LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 31.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,712 shares of the medical device company's stock after purchasing an additional 13,664 shares during the quarter. Great Lakes Advisors LLC's holdings in DexCom were worth $3,941,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of DXCM. Golden State Wealth Management LLC grew its stake in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in shares of DexCom during the 1st quarter worth approximately $27,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter worth approximately $38,000. Alpine Bank Wealth Management bought a new position in shares of DexCom during the 1st quarter worth approximately $40,000. Finally, Private Trust Co. NA boosted its stake in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after acquiring an additional 335 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on DXCM shares. Oppenheimer downgraded DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. Canaccord Genuity Group reiterated a "buy" rating and set a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. Argus started coverage on DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 target price for the company. Citigroup reiterated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Finally, Truist Financial started coverage on DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Stock Performance

NASDAQ:DXCM traded up $0.22 during mid-day trading on Friday, hitting $76.22. 3,054,556 shares of the stock were exchanged, compared to its average volume of 3,987,928. The stock has a market capitalization of $29.89 billion, a price-to-earnings ratio of 52.93, a price-to-earnings-growth ratio of 1.59 and a beta of 1.48. The firm's 50-day simple moving average is $80.88 and its 200 day simple moving average is $78.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period last year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Monday, July 28th. The stock was sold at an average price of $88.99, for a total value of $130,459.34. Following the completion of the transaction, the executive vice president directly owned 106,689 shares of the company's stock, valued at $9,494,254.11. The trade was a 1.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director directly owned 51,121 shares of the company's stock, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,237 shares of company stock worth $1,263,480. Corporate insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.